Bioenergetics and gene silencing approaches for unraveling nucleotide recognition by the human EIF2C2/Ago2 PAZ domain

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kandeel, Mahmoud ^b,c   Al Taher, Abdullah ^b   Nakashima, Remi ^a   Sakaguchi, Tomoya ^a   Kandeel, Ali ^d,e   Nagaya, Yuki ^a   Kitamura, Yoshiaki ^a   Kitade, Yukio ^a  

^a GIFU UNIVERSITY   (Japan)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

^c Kafrelsheikh University   (Egypt)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e Zagazig University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYL URIDINE MONOPHOSPHATE; ADENINE NUCLEOTIDE; ARGONAUTE 2 PROTEIN; DEOXYRIBONUCLEOTIDE; GUANOSINE PHOSPHATE; MICRORNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; URIDINE PHOSPHATE; ARGONAUTE PROTEIN; EIF2C2 PROTEIN, HUMAN; NUCLEOTIDE; PROTEIN BINDING;

ADENYLATION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; BIOENERGY; CONTROLLED STUDY; ENTHALPY; ENTROPY; GENE SILENCING; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PAZ DOMAIN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA INTERFERENCE; THERMODYNAMICS; CHEMICAL STRUCTURE; CHEMISTRY; DEFICIENCY; ENERGY METABOLISM; ENZYME SPECIFICITY; GENETICS; HEAT; HELA CELL LINE; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ARGONAUTE PROTEINS; BASE SEQUENCE; ENERGY METABOLISM; ENTROPY; HELA CELLS; HOT TEMPERATURE; HUMANS; MODELS, MOLECULAR; NUCLEOTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA, SMALL INTERFERING; SUBSTRATE SPECIFICITY;

EID: 84900392015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094538     Document Type: Article

References (47)

1. Montgomery MK (2004) RNA interference: historical overview and significance. Methods in molecular biology 265: 3-21.
2. Wang QC, Nie QH, Feng ZH (2003) RNA interference: antiviral weapon and beyond. World journal of gastroenterology: WJG 9: 1657-1661. (Pubitemid 37038108)
3. Jinek M, Doudna JA (2009) A three-dimensional view of the molecular machinery of RNA interference. Nature 457: 405-412.
4. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305: 1434-1437. (Pubitemid 39167656)
5. Riedmann LT, Schwentner R (2010) miRNA, siRNA, piRNA and argonautes: news in small matters. RNA biology 7: 133-139.
6. Haney SA (2007) Expanding the repertoire of RNA interference screens for developing new anticancer drug targets. Expert opinion on therapeutic targets 11: 1429-1441.
7. Mathupala SP, Mittal S, Guthikonda M, Sloan AE (2007) MicroRNA and brain tumors: a cause and a cure? DNA and cell biology 26: 301-310. (Pubitemid 46799179)
8. Zhang M, Wang J, Yao R, Wang L (2013) Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase: A Novel Therapeutic Strategy in Ovarian Cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society.
9. Bagasra O (2005) RNAi as an antiviral therapy. Expert opinion on biological therapy 5: 1463-1474.
10. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, et al. (2013) Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection. Molecular therapy: the journal of the American Society of Gene Therapy.
11. Bian Z, Xiao A, Cao M, Liu M, Liu S, et al. (2012) Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. Virology journal 9: 275.
12. Yang YJ, Zhao PS, Zhang T, Wang HL, Liang HR, et al. (2012) Small interfering RNAs targeting the rabies virus nucleoprotein gene. Virus research 169: 169-174.
13. Wu W, Wang T, Dong JJ, Liao ZL, Wen FQ (2012) Silencing of c-kit with small interference RNA attenuates inflammation in a murine model of allergic asthma. International journal of molecular medicine 30: 63-68.
14. Popescu FD, Popescu F (2007) A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics: targets & therapy 1: 271-283.
15. Courties G, Presumey J, Duroux-Richard I, Jorgensen C, Apparailly F (2009) RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert opinion on biological therapy 9: 535-538.
16. Kubowicz P, Zelaszczyk D, Pekala E (2013) RNAi in Clinical Studies. Current medicinal chemistry.
17. Ramachandran PV, Ignacimuthu S (2013) RNA Interference-A Silent but an Efficient Therapeutic Tool. Applied biochemistry and biotechnology.
18. Sasaki T, Shiohama A, Minoshima S, Shimizu N (2003) Identification of eight members of the Argonaute family in the human genome small star, filled. Genomics 82: 323-330. (Pubitemid 36957926)
19. Song JJ, Joshua-Tor L (2006) Argonaute and RNA - getting into the groove. Current opinion in structural biology 16: 5-11.
20. Lingel A, Simon B, Izaurralde E, Sattler M (2004) Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain. Nature structural & molecular biology 11: 576-577. (Pubitemid 38691927)
21. Ma JB, Ye K, Patel DJ (2004) Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429: 318-322. (Pubitemid 38684819)
22. Song JJ, Liu J, Tolia NH, Schneiderman J, Smith SK, et al. (2003) The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nature structural biology 10: 1026-1032. (Pubitemid 37500495)
23. Yan KS, Yan S, Farooq A, Han A, Zeng L, et al. (2003) Structure and conserved RNA binding of the PAZ domain. Nature 426: 468-474.
24. Lingel A, Simon B, Izaurralde E, Sattler M (2003) Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain. Nature 426: 465-469. (Pubitemid 37490135)
25. Gu S, Jin L, Huang Y, Zhang F, Kay MA (2012) Slicing-Independent RISC Activation Requires the Argonaute PAZ Domain. Current biology: CB 22: 1536-1542.
26. Taniho K, Nakashima R, Kandeel M, Kitamura Y, Kitade Y (2012) Synthesis and biological properties of chemically modified siRNAs bearing 1-deoxy-D-ribofuranose in their 3′-overhang region. Bioorganic & medicinal chemistry letters 22: 2518-2521.
27. Ueno Y, Kawada K, Naito T, Shibata A, Yoshikawa K, et al. (2008) Synthesis and silencing properties of siRNAs possessing lipophilic groups at their 3′-termini. Bioorganic & medicinal chemistry 16: 7698-7704.
28. Somoza A, Terrazas M, Eritja R (2010) Modified siRNAs for the study of the PAZ domain. Chemical communications 46: 4270-4272.
29. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, et al. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437-1441. (Pubitemid 39167657)
30. Maiti M, Nauwelaerts K, Lescrinier E, Herdewijn P (2011) Structural and binding study of modified siRNAs with the Argonaute 2 PAZ domain by NMR spectroscopy. Chemistry 17: 1519-1528.
31. Zeng L, Zhang Q, Yan K, Zhou MM (2011) Structural insights into piRNA recognition by the human PIWI-like 1 PAZ domain. Proteins 79: 2004-2009.
32. Tian Y, Simanshu DK, Ma JB, Patel DJ (2011) Structural basis for piRNA 2′-O-methylated 3′-end recognition by Piwi PAZ (Piwi/Argonaute/ Zwille) domains. Proceedings of the National Academy of Sciences of the United States of America 108: 903-910.
33. Simon B, Kirkpatrick JP, Eckhardt S, Reuter M, Rocha EA, et al. (2011) Recognition of 2′-O-methylated 3′-end of piRNA by the PAZ domain of a Piwi protein. Structure 19: 172-180.
34. Kandeel M, Kitade Y (2013) Computational Analysis of siRNA Recognition by the Ago2 PAZ Domain and Identification of the Determinants of RNA-Induced Gene Silencing. PloS one 8: e57140.
35. Kandeel M, Kitade Y (2013) In silico molecular docking analysis of the human Argonaute 2 PAZ domain reveals insights into RNA interference. Journal of computer-aided molecular design 27: 605-614.
36. Kandeel M, Kitade Y (2011) Binding dynamics and energetic insight into the molecular forces driving nucleotide binding by guanylate kinase. Journal of molecular recognition: JMR 24: 322-332.
37. Kandeel M, Kitade Y (2010) Substrate specificity and nucleotides binding properties of NM23H2/nucleoside diphosphate kinase homolog from Plasmodium falciparum. Journal of bioenergetics and biomembranes 42: 361-369.
38. Kandeel M, Kitade Y (2011) The substrate binding preferences of Plasmodium thymidylate kinase. Biological & pharmaceutical bulletin 34: 173-176.
39. Kandeel M, Miyamoto T, Kitade Y (2009) Bioinformatics, enzymologic properties, and comprehensive tracking of Plasmodium falciparum nucleoside diphosphate kinase. Biological & pharmaceutical bulletin 32: 1321-1327.
40. Sigurskjold BW (2000) Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Analytical biochemistry 277: 260-266.
41. Nakanishi K, Weinberg DE, Bartel DP, Patel DJ (2012) Structure of yeast Argonaute with guide RNA. Nature 486: 368-374.
42. Ho T, Wang L, Huang L, Li Z, Pallett DW, et al. (2010) Nucleotide bias of DCL and AGO in plant anti-virus gene silencing. Protein & cell 1: 847-858.
43. Juvvuna PK, Khandelia P, Lee LM, Makeyev EV (2012) Argonaute identity defines the length of mature mammalian microRNAs. Nucleic acids research 40: 6808-6820.
44. Burroughs AM, Ando Y, de Hoon MJ, Tomaru Y, Nishibu T, et al. (2010) A comprehensive survey of 3′ animal miRNA modification events and a possible role for 3′ adenylation in modulating miRNA targeting effectiveness. Genome research 20: 1398-1410.
45. Petri S, Dueck A, Lehmann G, Putz N, Rudel S, et al. (2011) Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA 17: 737-749.
46. Ueno Y, Inoue T, Yoshida M, Yoshikawa K, Shibata A, et al. (2008) Synthesis of nuclease-resistant siRNAs possessing benzene-phosphate backbones in their 3′-overhang regions. Bioorganic & medicinal chemistry letters 18: 5194-5196.
47. Ueno Y, Watanabe Y, Shibata A, Yoshikawa K, Takano T, et al. (2009) Synthesis of nuclease-resistant siRNAs possessing universal overhangs. Bioorganic & medicinal chemistry 17: 1974-1981.